Navigation Links
Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
Date:6/8/2009

from the ITCA 650 phase 1b study have provided important guidance toward dose selection and study design for continuing clinical development," said Kenneth L. Luskey, MD, VP Clinical Research at Intarcia. "A phase 2 study of ITCA 650 is planned for the third quarter of this year. In this trial we intend to confirm the Phase 1b results on a larger scale and for a longer duration to further characterize the glucose lowering effects and tolerability of ITCA 650."

ITCA 650 therapy in this phase 1b trial was administered for the full course of treatment with a single insertion of the ITCA 650 on day 1 and removal on day 29. The phase 2 trial will evaluate ITCA 650 against the current standard of care for a longer duration of treatment and among a larger population of type 2 diabetes patients. The goals of the ITCA 650 program are to enhance the therapeutic effects of exenatide by ensuring patient compliance and providing more consistent, round-the-clock therapeutic drug levels; and to reduce side effects, including nausea associated with high peak levels of exenatide exposure observed with repeated injections.

About ITCA 650

ITCA 650 therapy for type 2 diabetes consists of DUROS continuous delivery of exenatide. The DUROS delivery technology comprises the DUROS device, a matchstick-size miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and proprietary formulation technology that maintains stability of therapeutic proteins and peptides at human body temperature for extended periods of time. The DUROS technology can deliver up to a full year of therapy from a single ITCA 650 insertion. Unlike other extended delivery technologies, such as polymers or albumin fusions, DUROS delivery allows for steady state drug delivery upon insertion and near immediate withdrawal of therapy to manage side effects, if required. Exenatide, the active agent in ITCA 650, has been approved in t
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
2. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
3. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
6. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
7. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
9. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 Tauriga Sciences, ... diversified life sciences company, today announced that its stockholders ... of common stock of the Company from 1,000,000,000 to ... July 27, 2015 at the Law Offices of Nixon ... the Special Meeting, there were 480,655,929 shares of common ...
(Date:7/28/2015)... N.J. , July 28, 2015  Moerae ... second Phase 1 clinical trial with MMI-0100, a ... is being developed for pulmonary disorders characterized by ... United Kingdom , is a ... further evaluating the safety and tolerability of MMI-0100 ...
(Date:7/28/2015)... 2015 CSL Behring announced today ... for review the company,s Biologics License Application (BLA) for ... the treatment of hemophilia A. In the pivotal clinical ... Hemophilia A is a congenital bleeding disorder ... affected patients are male. People with hemophilia A may ...
(Date:7/28/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., ... UTHR ) today announced its financial results for ... "Orenitram ®  sales grew nearly 300% as compared ... product was first launched," said Roger Jeffs, Ph.D., ... growth in Orenitram sales was due to an ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... , Key words: ... • SPA Imaging Beads , ... is a neurotransmitter/hormone with a wide range of biological actions (1–3) ... Alzheimer’s and Parkinson’s diseases. The SS analog, octreotide (SMS 201–995), is ...
... Key words: EFC chemiluminescence ... , Competitive ... and sensitivity remain vital concerns, particularly for common screens such as ... demands by combining excellent detection with the ability to image whole ...
... of Data into Gems of Knowledge Using discoveryHub™ ... , This paper discusses key problems and opportunities ... and complexity of life science data available today, and ... that enables rapid ‘harvesting’ and analysis of critical scientific ...
Cached Biology Technology:The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 2The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 3The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 4The development of a somatostatin sst4 receptor-binding assay using the LEADseeker Multimodality Imaging System 5Use of the HitHunter EFC Chemiluminescent Detection Kits with LEADseeker Multimodality Imaging System 2Use of the HitHunter EFC Chemiluminescent Detection Kits with LEADseeker Multimodality Imaging System 3Use of the HitHunter EFC Chemiluminescent Detection Kits with LEADseeker Multimodality Imaging System 4Exploiting the Life Science Data Explosion to Speed New Drug Discovery 2Exploiting the Life Science Data Explosion to Speed New Drug Discovery 3Exploiting the Life Science Data Explosion to Speed New Drug Discovery 4Exploiting the Life Science Data Explosion to Speed New Drug Discovery 5Exploiting the Life Science Data Explosion to Speed New Drug Discovery 6Exploiting the Life Science Data Explosion to Speed New Drug Discovery 7Exploiting the Life Science Data Explosion to Speed New Drug Discovery 8Exploiting the Life Science Data Explosion to Speed New Drug Discovery 9Exploiting the Life Science Data Explosion to Speed New Drug Discovery 10Exploiting the Life Science Data Explosion to Speed New Drug Discovery 11Exploiting the Life Science Data Explosion to Speed New Drug Discovery 12Exploiting the Life Science Data Explosion to Speed New Drug Discovery 13Exploiting the Life Science Data Explosion to Speed New Drug Discovery 14Exploiting the Life Science Data Explosion to Speed New Drug Discovery 15Exploiting the Life Science Data Explosion to Speed New Drug Discovery 16Exploiting the Life Science Data Explosion to Speed New Drug Discovery 17
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... high intensity sprintsknown to benefit muscle and improve exercise ... in particular arteries that deliver blood to our muscles ... The study, lead by kinesiology doctoral student Mark ... of Physiology. Regulatory, Integrative & Comparative Physiology. ...
... JOSE, Calif., June 2 Atmel(R) Corporation (Nasdaq:,ATML), ... technology and,solutions, announced today that its FingerChip(R) fingerprint ... for its RX5622 LCD PC.,Rise will showcase this ... Atmel,s FingerChip solution as a standard feature ...
... WI, JUNE 2, 2008-- An understanding how environmental ... transport and fate of agricultural chemicals in the ... degradation of surface and ground waters from past, ... has been conducted at field or smaller scales, ...
Cached Biology News:Brief, intense exercise benefits the heart 2Atmel's FingerChip Biometric Sensor Selected by Rise Computer for its Robust Security 2Atmel's FingerChip Biometric Sensor Selected by Rise Computer for its Robust Security 3Holistic understanding: Ag chemicals in the environment 2